tbuckley/cabot-search huggingface dataset:
Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization
Authors: Sara Y. Tartof, Lei Qian, Vennis Hong, Rong Wei, Ron F. Nadjafi, Heidi Fischer, Zhuoxin Li, Sally F. Shaw, Susan L. Caparosa, Claudia L. Nau, Tanmai Saxena, Gunter K. Rieg, Bradley K. Ackerson, Adam L. Sharp, Jacek Skarbinski, Tej K. Naik, Sameer B. Murali
Journal: Annals of Internal Medicine (2020)

Obesity, race/ethnicity, and other correlated characteristics have emerged as high-profile risk factors for adverse coronavirus disease 2019 (COVID-19)–associated outcomes, yet studies have not adequately disentangled their effects.
Genetic analyses identify GSDMB associated with asthma severity, exacerbations, and antiviral pathways
Authors: Xingnan Li, Stephanie A. Christenson, Brian Modena, Huashi Li, William W. Busse, Mario Castro, Loren C. Denlinger, Serpil C. Erzurum, John V. Fahy, Benjamin Gaston, Annette T. Hastie, Elliot Israel, Nizar N. Jarjour, Bruce D. Levy, Wendy C. Moore, Prescott G. Woodruff, Naftali Kaminski, Sally E. Wenzel, Eugene R. Bleecker, Deborah A. Meyers
Journal: Journal of Allergy and Clinical Immunology (2020)
Safety and Efficacy of Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: Results of a Prospective Multicenter Phase I/II Clinical Trial
Authors: Peter J. Lang, Paul G. Schlegel, Roland Meisel, Ansgar S. Schulz, Johann Greil, Peter Bader, Sandra Karitzky, Silke Holtkamp, Christiane Siewert, Stefanie Pflitsch, Michael Schumm, Matthias K. Eyrich, Markus Wiesneth, Halvard Bonig, Rupert Handgretinger
Journal: Blood (2017)
The ETO2-GLIS2 Fusion Oncogene Alters Early Human Hematopoiesis in an Induced Pluripotent Stem Cells-Derived Model of Pediatric Acute Megakaryoblastic Leukemia
Authors: Salvatore Nicola Bertuccio, Marie Cambot, Cécile K Lopez, Larissa Lordier, Alessandro Donada, Zakia Aid, Franco Locatelli, Riccardo Masetti, William Vainchenker, Hana Raslova, Andrea Pession, Thomas Mercher
Journal: Blood (2017)
Face Coverings in a Pandemic
Authors: Matthew D. McGraw, Satya Achanta, Jessica Castner, Diane R. Gold, Stella E Hines, Carrie A. Redlich, Marianna M. Sockrider
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

"Face Coverings in a Pandemic." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp. –
COVID-19 and how evidence of a new disease evolves
Authors: Féline P B Kroon, Ted R Mikuls, Robert BM Landewé
Journal: Annals of the Rheumatic Diseases (2020)

In 7 months’ time, COVID-19 has developed from a single case to a pandemic affecting more than nine million people worldwide, and the outlook of many more to come. While the majority fare a mild disease course, the world has seen large numbers of critically ill and deaths. These are unprecedented times, in modern history only comparable to the 1918 Spanish influenza,1 as we are faced by the worldwide spread of a disease that was non-existent less than a year ago.

‘Evidence-based medicine’ is proudly rooted in our practice nowadays and also expected to provide us with guidance on how to respond to COVID-19. As a result, the number of studies on COVID-19 is increasing exponentially. The accumulating data are widely available owing to the ‘digital era’ we live in, which, despite obvious advantages of public availability of information, also poses risks of ‘information overload’ or ‘fake news’.

The rapid increase in research on COVID-19 is encouraging, yet, it is important …
Physician Orders for Life-Sustaining Treatment and ICU Admission Near the End of Life—Reply
Authors: Robert Y. Lee, J. Randall Curtis, Erin K. Kross
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Home Health Care Use and Post-Discharge Outcomes After Heart Failure Hospitalizations
Authors: Madeline R Sterling, Lisa M Kern, Monika M Safford, Christine D Jones, Penny H Feldman, Gregg C Fonarow, Shubin Sheng, Roland A Matsouaka, Adam D DeVore, Barbara Lytle, Haolin Xu, Larry A Allen, Anita Deswal, Clyde W Yancy, Nancy M Albert
Journal: JACC Heart Failure (2020)
Abstract 38: Molecular determinants of drug response in TNBC cell lines
Authors: Nathan M. Merrill, Eric J. Lachacz, Nathalie M. Vandecan, Peter J. Ulintz, Li Wei Bao, John P. Lloyd, Aki Morikawa, Sofia D. Merajver, Matthew B. Soellner
Journal: Clinical Cancer Research (2020)

Abstract Triple-negative breast cancer (TNBC) is one of the deadliest forms of breast cancer due to limited treatment options beyond conventional chemotherapy. TNBC constitutes approximately 10-20% of total breast cancer cases in the US; however, TNBC tends to be more aggressive, higher grade, and have a poorer prognosis than other forms of breast cancer. While oncogenic aberrations have been identified in TNBC, such as the PI3K/AKT/mTOR pathway that is misregulated in ~25% of tumors, there is a general lack of predictive markers of therapeutic efficacy to identify subsets of patients most likely to positively respond to a given targeted or conventional therapy. Simply relying on mutation status is undependable, as some patients without PI3K mutations respond to PI3K inhibitors and some patients with PI3K mutations do not respond. Thus, there is a critical need for biomarkers of drug efficacy in TNBC to help design precision medicine clinical trials based on systematically derived predictive biomarkers. To fill this gap, we devised a strategy to identify biomarkers of drug efficacy in TNBC. Using 23 TNBC cell lines, drug sensitivity scores (DSS3) were determined across a panel of investigational drugs and drugs approved for other indications. Molecular readouts were generated for each cell line using RNA sequencing, RNA targeted panels, DNA sequencing, and functional proteomics. DSS3 values were correlated with molecular readouts using an FDR-corrected significance cutoff of p* &amp;lt; 0.05 and yielded molecular determinant panels that predict anti-TNBC efficacy. Molecular determinant panels were obtained from 12 drugs that were prioritized on the basis of their efficacy. Six molecular determinant panels were obtained by correlating DSS3 with molecular readouts. We found that coinhibiting correlated pathways led to robust synergy across many cell lines. Together, our work presents an integrated method to identify biomarkers of drug efficacy in TNBC, where DNA predictions correlate poorly with drug response. Furthermore, we outline a framework to identify optimal companion drugs for combination therapy. Citation Format: Nathan M. Merrill, Eric J. Lachacz, Nathalie M. Vandecan, Peter J. Ulintz, Li Wei Bao, John P. Lloyd, Aki Morikawa, Sofia D. Merajver, Matthew B. Soellner. Molecular determinants of drug response in TNBC cell lines [abstract]. In: Proceedings of the AACR Special Conference on Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies; Jan 9-12, 2020; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(12_Suppl_1):Abstract nr 38.
Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
Authors: Zhihao Lu, Huan Chen, Shuang Li, Jifang Gong, Jian Li, Jianling Zou, Lihong Wu, Jianing Yu, Wenbo Han, Huaibo Sun, Xi Jiao, Xiaotian Zhang, Zhi Peng, Ming Lu, Zhenghang Wang, Henghui Zhang, Lin Shen
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background Despite the great achievements made in immune-checkpoint-blockade (ICB) in cancer therapy, there are no effective predictive biomarkers in gastrointestinal (GI) cancer. Methods This study included 93 metastatic GI patients treated with ICBs. The first cohort comprising 73 GI cancer patients were randomly assigned into discovery (n=44) and validation (n=29) cohorts. Comprehensive genomic profiling was performed on all samples to determine tumor mutational burden (TMB) and copy-number alterations (CNAs). A subset of samples was collected for RNA immune oncology (IO) panel sequencing, microsatellite instability (MSI)/mismatch repair and program death ligand 1 (PD-L1) expression evaluation. In addition, 20 gastric cancer (GC) patients were recruited as the second validation cohort. Results In the first cohort of 73 GI cancer patients, a lower burden of CNA was observed in patients with durable clinical benefit (DCB). In both the discovery (n=44) and validation (n=29) subsets, lower burden of CNA was associated with an improved clinical benefit and better overall survival (OS). Efficacy also correlated with a higher TMB. Of note, a combinatorial biomarker of TMB and CNA may better stratify DCB patients from ICB treatment, which was further confirmed in the second validation cohort of 20 GC patients. Finally, patients with lower burden of CNA revealed increased immune signatures in our cohort and The Cancer Genome Atlas data sets as well. Conclusions Our results suggest that the burden of CNA may have superior predictive value compared with other signatures, including PD-L1, MSI and TMB. The joint biomarker of CNA burden and TMB may better stratify DCB patients, thereby providing a rational choice for GI patients treated with ICBs.
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
Authors: Nadine Abdallah, S. Vincent Rajkumar, Patricia Greipp, Prashant Kapoor, Morie A. Gertz, Angela Dispenzieri, Linda B. Baughn, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, David Dingli, Ronald S. Go, Yi L. Hwa, Amie Fonder, Miriam Hobbs, Yi Lin, Nelson Leung, Taxiarchis Kourelis, Rahma Warsame, Mustaqeem Siddiqui, John Lust, Robert A. Kyle, Leif Bergsagel, Rhett Ketterling, Shaji K. Kumar
Journal: Blood Cancer Journal (2020)

Abstract Cytogenetic abnormalities are found in most multiple myeloma (MM) patients. Although their prognostic value has been well studied, there are limited data on the association of primary cytogenetic abnormalities with disease characteristics and treatment response. This study was designed to evaluate these associations. This is a retrospective study including 2027 Mayo Clinic patients diagnosed with MM between February 2004 and February 2018 who had cytogenetic testing by FISH at diagnosis. Translocations t(4;14), t(14;16), t(6;14), and t(14;20) were associated with anemia, beta2microglobulin &gt;5.5 µg/ml and ≥50% bone marrow plasma cells; t(4;14) was associated with higher serum monoclonal protein and plasma cell proliferation. Overall response rate to proteasome inhibitor (PI)-based treatment was higher for IgH translocations compared to trisomies (83% vs. 71%, P = 0.002), but was higher for trisomies with immunomodulatory drug (IMiD)-based treatment (87% vs. 75%, P &lt; 0.001). Time to next treatment was longer with trisomies than IgH translocation with IMiD-based (32.1 vs. 18.4 months, P &lt; 0.001) and PI + IMiD-based (44.0 vs. 27.4 months, P = 0.003) treatments. Outcomes were superior with PI + IMiD combinations in all groups. Our results show that t(4;14), t(14;16), t(6;14), and t(14;20) are associated with high-risk disease characteristics, and IgH translocations and trisomies may be associated with better responses to PIs and IMiDs, respectively.
Characterization and Genotype-Phenotype Correlation of Fanconi Anemia Patients in Israel
Authors: Orna Steinberg Shemer, Tracie Goldberg, Joanne Yacobovich, Carina Levin, Ariel Koren, Shoshana Revel-Vilk, Tal Ben-Ami, Amir A Kuperman, Vered Shkalim, Amos Toren, Joseph Kapelushnik, Ayelet Ben-Barak, Hagit Miskin, Tanya Krasnov, Sharon Noy-Lotan, Orly Dgany, Hannah Tamary
Journal: Blood (2017)
Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study
Authors: Matthieu Schmidt, David Hajage, Guillaume Lebreton, Antoine Monsel, Guillaume Voiriot, David Levy, Elodie Baron, Alexandra Beurton, Juliette Chommeloux, Paris Meng, Safaa Nemlaghi, Pierre Bay, Pascal Leprince, Alexandre Demoule, Bertrand Guidet, Jean Michel Constantin, Muriel Fartoukh, Martin Dres, Alain Combes, Charles-Edouard Luyt, Guillaume Hekimian, Nicolas Brechot, Marc Pineton de Chambrun, Cyrielle Desnos, Jeremy Arzoine, Emmanuelle Guerin, Thibaut Schoell, Pierre Demondion, Charles Juvin, Nathalie Nardonne, Sofica Marin, Cossimo D'Alessandro, Bao-Long Nguyen, Cyril Quemeneur, Arthur James, Mona Assefi, Victoria Lepere, Guillaume Savary, Aude Gibelin, Matthieu Turpin, Alexandre Elabbadi, Enora Berti, Corinne Vezinet, Harold Bonvallot, Pierre-Romain Delmotte, Martin De Sarcus, Charlotte Du Fayet De La Tour, Samia Abbas, Eric Maury, Jean-Luc Baudel, Jean-Remi Lavillegrand, Hafid Ait Oufella, Abdelmalek Abdelkrim, Thomas Urbina, Sara Virolle, Robin Deleris, Vincent Bonny, Julien Le Marec, Julien Mayaux, Elise Morawiec
Journal: The Lancet Respiratory Medicine (2020)
Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial
Authors: Richard J McManus, Paul Little, Beth Stuart, Katherine Morton, James Raftery, Jo Kelly, Katherine Bradbury, Jin Zhang, Shihua Zhu, Elizabeth Murray, Carl R May, Frances S Mair, Susan Michie, Peter Smith, Rebecca Band, Emma Ogburn, Julie Allen, Cathy Rice, Jacqui Nuttall, Bryan Williams, Lucy Yardley
Journal: BMJ (2021)

Abstract Objective The HOME BP (Home and Online Management and Evaluation of Blood Pressure) trial aimed to test a digital intervention for hypertension management in primary care by combining self-monitoring of blood pressure with guided self-management. Design Unmasked randomised controlled trial with automated ascertainment of primary endpoint. Setting 76 general practices in the United Kingdom. Participants 622 people with treated but poorly controlled hypertension (&gt;140/90 mm Hg) and access to the internet. Interventions Participants were randomised by using a minimisation algorithm to self-monitoring of blood pressure with a digital intervention (305 participants) or usual care (routine hypertension care, with appointments and drug changes made at the discretion of the general practitioner; 317 participants). The digital intervention provided feedback of blood pressure results to patients and professionals with optional lifestyle advice and motivational support. Target blood pressure for hypertension, diabetes, and people aged 80 or older followed UK national guidelines. Main outcome measures The primary outcome was the difference in systolic blood pressure (mean of second and third readings) after one year, adjusted for baseline blood pressure, blood pressure target, age, and practice, with multiple imputation for missing values. Results After one year, data were available from 552 participants (88.6%) with imputation for the remaining 70 participants (11.4%). Mean blood pressure dropped from 151.7/86.4 to 138.4/80.2 mm Hg in the intervention group and from 151.6/85.3 to 141.8/79.8 mm Hg in the usual care group, giving a mean difference in systolic blood pressure of −3.4 mm Hg (95% confidence interval −6.1 to −0.8 mm Hg) and a mean difference in diastolic blood pressure of −0.5 mm Hg (−1.9 to 0.9 mm Hg). Results were comparable in the complete case analysis and adverse effects were similar between groups. Within trial costs showed an incremental cost effectiveness ratio of £11 ($15, €12; 95% confidence interval £6 to £29) per mm Hg reduction. Conclusions The HOME BP digital intervention for the management of hypertension by using self-monitored blood pressure led to better control of systolic blood pressure after one year than usual care, with low incremental costs. Implementation in primary care will require integration into clinical workflows and consideration of people who are digitally excluded. Trial registration ISRCTN13790648 .
A Pregnant Woman in Her 30s With a Heart Murmur
Authors: Katia Bravo-Jaimes, Daniel Ocazionez
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Physician-Reported Misuse of Thyroid Ultrasonography
Authors: Debbie W. Chen, David Reyes-Gastelum, Archana Radhakrishnan, Ann S. Hamilton, Kevin C. Ward, Megan R. Haymart
Journal: JAMA Surgery (2020)

Correction: This article was corrected on October 21, 2020, to fix numbers placed out of order on the x-axes in Figure 1 and incorrect word placement in Figure 2, with "General surgery site," corrected to "General surgery," "Los Angeles County practice" corrected to "Los Angeles County site," and "Setting" corrected to "Practice setting."Correction: This article was corrected on October 21, 2020, to fix numbers placed out of order on the x-axes in Figure 1 and incorrect word placement in Figure 2, with "General surgery site," corrected to "General surgery," "Los Angeles County practice" corrected to "Los Angeles County site,
Association of Low Muscle Mass and Low Muscle Radiodensity With Morbidity and Mortality for Colon Cancer Surgery
Authors: Jingjie Xiao, Bette J. Caan, Elizabeth M. Cespedes Feliciano, Jeffrey A. Meyerhardt, Peter D. Peng, Vickie E. Baracos, Valerie S. Lee, Sora Ely, Rebecca C. Gologorsky, Erin Weltzien, Candyce H. Kroenke, Marilyn L. Kwan, Stacey E. Alexeeff, Adrienne L. Castillo, Carla M. Prado
Journal: JAMA Surgery (2020)

<h3>Importance</h3> Given the risks of postoperative morbidity and its consequent economic burden and impairment to patients undergoing colon resection, evaluating risk factors associated with complications will allow risk stratification and the targeting of supportive interventions. Evaluation of muscle characteristics is an emerging area for improving preoperative risk stratification. <h3>Objective</h3> To examine the associations of muscle characteristics with postoperative complications, length of hospital stay (LOS), readmission, and mortality in patients with colon cancer. <h3>Design, Setting, and Participants</h3> This population-based retrospective cohort study was conducted among 1630 patients who received a diagnosis of stage I to III colon cancer from January 2006 to December 2011 at Kaiser Permanente Northern California, an integrated health care system. Preliminary data analysis started in 2017. Because major complication data were collected between 2018 and 2019, the final analysis using the current cohort was conducted between 2019 and 2020. <h3>Exposures</h3> Low skeletal muscle index (SMI) and/or low skeletal muscle radiodensity (SMD) levels were assessed using preoperative computerized tomography images. <h3>Main Outcomes and Measures</h3> Length of stay, any complication (≥1 predefined complications) or major complications (Clavien-Dindo classification score ≥3), 30-day mortality and readmission up to 30 days postdischarge, and overall mortality. <h3>Results</h3> The mean (SD) age at diagnosis was 64.0 (11.3) years and 906 (55.6%) were women. Patients with low SMI or low SMD were more likely to remain hospitalized 7 days or longer after surgery (odds ratio [OR], 1.33; 95% CI, 1.05-1.68; OR, 1.39; 95% CI, 1.05-1.84, respectively) and had higher risks of overall mortality (hazard ratio, 1.40; 95% CI, 1.13-1.74; hazard ratio, 1.44; 95% CI, 1.12-1.85, respectively). Additionally, patients with low SMI were more likely to have 1 or more postsurgical complications (OR, 1.31; 95% CI, 1.04-1.65) and had higher risk of 30-day mortality (OR, 4.85; 95% CI, 1.23-19.15). Low SMD was associated with higher odds of having major complications (OR, 2.41; 95% CI, 1.44-4.04). <h3>Conclusions and Relevance</h3> Low SMI and low SMD were associated with longer LOS, higher risk of postsurgical complications, and short-term and long-term mortality. Research should evaluate whether targeting potentially modifiable factors preoperatively, such as preserving muscle mass, could reverse the observed negative associations with postoperative outcomes.